Active, not recruitingPhase 2NCT04053803
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
Studying Sickle cell anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Imara, Inc.
- Principal Investigator
- Karen Tang, MDImara, Inc.
- Intervention
- IMR-687(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Study locations (7)
- University of Connecticut Health Center, Farmington, Connecticut, United States
- Foundation for Sickle Cell Disease Research, Hollywood, Florida, United States
- Baylor Scott & White Medical Center - Temple, Temple, Texas, United States
- Bristol Haematology and Oncology Centre, Bristol, United Kingdom
- University College London Hospital NHS Foundation Trust, London, United Kingdom
- Guy's and St Thomas Hospital CRF, London, United Kingdom
- Royal London Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04053803 on ClinicalTrials.govOther trials for Sickle cell anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07369024Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsMohsen Saidinejad
- RECRUITINGNCT07373639A Long-term Follow-up Study in Patients Who Received BEAM-101Beam Therapeutics Inc.
- RECRUITINGNANCT07402811Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell DiseaseUniversity of Illinois at Chicago
- RECRUITINGPHASE1NCT06647979Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesDaniel Bauer
- RECRUITINGNANCT06555939Promoting Resilience Among Adolescents and Young Adults With Sickle Cell DiseaseBoston Children's Hospital
- RECRUITINGPHASE3NCT06975865The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseSanofi
- RECRUITINGNCT06944067Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell DiseaseNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT06923111PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]Nova Laboratories Limited